Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23507688,run time,Reversed-phase chromatography using a gradient elution with methanol and 0.04% formic acid solution (pH 3.5) was used for separation in a run time of 5 min.,Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),min,5,1583,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,300.4,1584,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,215.2,1585,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1586,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,152.0,1587,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,462.2,1588,DB00318,Codeine
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1589,DB00318,Codeine
,23507688,response,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-80,1590,DB00318,Codeine
,23507688,response range,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-5.0,1591,DB00318,Codeine
,8032582,half-life,"Furthermore, the similar half-life of both drugs (2-2.5 h) is advantageous for a fixed drug combination.",Pharmacokinetic evaluation of two ibuprofen-codeine combinations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032582/),h,2-2.5,2335,DB00318,Codeine
,7205649,volume of distribution,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[l] / [kg],7.58,3860,DB00318,Codeine
,7205649,elimination T 1/2,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),min,88.6,3861,DB00318,Codeine
,7205649,plasma clearance,The mean volume of distribution is 7.58 +/- 0.87 liters/kg; the mean elimination T 1/2 is 88.6 +/- 1.9 min and the plasma clearance is 59.3 +/- 1.4 ml/min/kg.,Methadone: radioimmunoassay and pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205649/),[ml] / [kg·min],59.3,3862,DB00318,Codeine
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,106,6999,DB00318,Codeine
,9725479,relative bioavailabilities,"The relative bioavailabilities of codeine and ibuprofen (alone or in association) were 106 +/- 24% (mean +/- sd) and 101 +/- 19%, respectively.",Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725479/),%,101,7000,DB00318,Codeine
,2401756,peak codeine plasma concentrations,The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],88.1,8582,DB00318,Codeine
,2401756,tmax (,The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],88.1,8583,DB00318,Codeine
,2401756,time to reach maximum plasma codeine concentrations),The mean peak codeine plasma concentrations and tmax (time to reach maximum plasma codeine concentrations) were 88.1 ng/mL and 1.2 hours.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),h,1.2,8584,DB00318,Codeine
,2401756,maximum concentrations,Mean maximum concentrations of metabolically produced morphine was 2.7 +/- 0.6 ng/mL.,Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401756/),[ng] / [ml],2.7,8585,DB00318,Codeine
,27300254,half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,50.2,8778,DB00318,Codeine
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,24.5,8779,DB00318,Codeine
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,3-6,8780,DB00318,Codeine
,27300254,half-life,"After cessation of dosing, the rate of urinary elimination decreased significantly (F3,23 = 247: P < 0.05, n = 6) in a predictable manner with low intersubject variability and a half-life of 16.1 ± 3.8 h (n = 10).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,16.1,8781,DB00318,Codeine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.88,10593,DB00318,Codeine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.73,10594,DB00318,Codeine
,23165127,hair elimination half-lives,"Assuming a rate of hair growth of 1cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively.","Disappearance of 6-acetylmorphine, morphine and codeine from human scalp hair after discontinuation of opiate abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23165127/),month,0.61,10595,DB00318,Codeine
,9248943,flow rate,The chromatographic separation of the analytes was achieved using a normal phase column and a water-methanol-acetonitrile-formic acid mobile phase at a flow rate of 230 microL/min.,"Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μl] / [min],230,13068,DB00318,Codeine
,9248943,peak concentration,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],0.93,13069,DB00318,Codeine
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],9.6,13070,DB00318,Codeine
,9248943,peak concentrations,"6-monoacetylmorphine showed a peak concentration of 0.93 micrograms/mL serum at 3 min, whereas morphine and morphine-3-glucuronide achieved their peak concentrations of 9.6 and 2.9 micrograms/mL serum at 10 and 20 min, respectively.","Simultaneous determination of heroin 6-monoacetylmorphine, morphine, and its glucuronides by liquid chromatography--atmospheric pressure ionspray-mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248943/),[μg] / [ml·serum],2.9,13071,DB00318,Codeine
,26309104,terminal half-life,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,1.56,15188,DB00318,Codeine
,26309104,maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],155.6,15189,DB00318,Codeine
,26309104,time to maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.90,15190,DB00318,Codeine
,26309104,maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],7.90,15191,DB00318,Codeine
,26309104,time to maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.47,15192,DB00318,Codeine
,26309104,terminal half-life,"The terminal half-life for hydrocodone was 15.85 hours, but was likely influenced by delayed drug absorption in some dogs and may not have been a robust estimate.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,15.85,15193,DB00318,Codeine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,72.8,17212,DB00318,Codeine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,80.2,17213,DB00318,Codeine
,29016880,maximum effect,"Mean maximum effect for ""at the moment"" Drug Liking was significantly (P < 0.01) lower for intranasal hydrocodone ER (72.8) compared with hydrocodone powder (80.2) and HYD-OF (83.2).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,83.2,17214,DB00318,Codeine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,68.5,17215,DB00318,Codeine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,77.1,17216,DB00318,Codeine
,29016880,Overall Drug Liking maximum effect,"Similar results were observed for Overall Drug Liking maximum effect (68.5 vs 77.1 and 79.8, respectively; P < 0.01).","Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016880/),,79.8,17217,DB00318,Codeine
,22973910,V(d),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),l,193,17347,DB00318,Codeine
,22973910,k(a),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),1/[h],0.336,17348,DB00318,Codeine
,22973910,T(lag),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),h,0.859,17349,DB00318,Codeine
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,67,25062,DB00318,Codeine
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,74,25063,DB00318,Codeine
,20444020,T(1/2),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,1.22,28839,DB00318,Codeine
,20444020,clearance,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ml] / [kg·min],29.94,28840,DB00318,Codeine
,20444020,volume of distribution,"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[l] / [kg],3.17,28841,DB00318,Codeine
,20444020,C(max),"Codeine was rapidly eliminated after i.v. administration (T(1/2) = 1.22 h; clearance = 29.94 mL/min/kg; volume of distribution = 3.17 L/kg) with negligible amounts of morphine present, but large amounts of codeine-6-glucuronide (C(max) = 735.75 ng/mL) were detected.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],735.75,28842,DB00318,Codeine
,20444020,oral bioavailability,"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),%,4,28843,DB00318,Codeine
,20444020,C(max),"The oral bioavailability of codeine was 4%, morphine concentrations were negligible, but large amounts of codeine-6-glucuronide (C(max) = 1952.86 ng/mL) were detected suggesting substantial first pass metabolism.","Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[ng] / [ml],1952.86,28844,DB00318,Codeine
,20444020,C(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),[μg] / [ml],6.74,28845,DB00318,Codeine
,20444020,T(max),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.85,28846,DB00318,Codeine
,20444020,T(1/2),Acetaminophen was rapidly absorbed (C(max) = 6.74 microg/mL; T(max) = 0.85 h) and eliminated (T(1/2) = 0.96 h).,"Pharmacokinetics of acetaminophen, codeine, and the codeine metabolites morphine and codeine-6-glucuronide in healthy Greyhound dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444020/),h,0.96,28847,DB00318,Codeine
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],24.3,29288,DB00318,Codeine
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],29.5,29289,DB00318,Codeine
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,0.9,30364,DB00318,Codeine
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30365,DB00318,Codeine
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,1.9,30366,DB00318,Codeine
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2.2,30367,DB00318,Codeine
,22541841,absolute bioavailability,"The absolute bioavailability of naloxone was higher following rectal administration compared with oral administration, but was still low at 15%.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,15,30368,DB00318,Codeine
≤,22541841,oral absolute bioavailability,The mean oral absolute bioavailability of naloxone in this study was ≤ 2% at doses ranging from 5 mg to 120 mg.,Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30369,DB00318,Codeine
,9696456,pain tolerance,"Compared to placebo, 20 mg morphine caused a significant increase in pain tolerance in both phenotypes, EMs and PMs (16.2+/-27.4 vs. -0.66+/-27.4 s x h, n=18).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),h·s,16.2,35418,DB00318,Codeine
,9696456,pain tolerance,"Compared to placebo, 20 mg morphine caused a significant increase in pain tolerance in both phenotypes, EMs and PMs (16.2+/-27.4 vs. -0.66+/-27.4 s x h, n=18).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),h·s,-0.66,35419,DB00318,Codeine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],44,35420,DB00318,Codeine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],199,35421,DB00318,Codeine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],48,35422,DB00318,Codeine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],210,35423,DB00318,Codeine
,9696456,Cmax,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],38,35424,DB00318,Codeine
,9696456,AUC,"Whereas morphine plasma concentrations were similar in PMs (Cmax: 44+/-13 nmol/l: AUC: 199+/-45 nmol x h/l) and EMs (Cmax: 48+/-17 nmol/l); AUC: 210+/-65 nmol x h/l) after morphine administration, following 170 mg codeine, morphine plasma concentrations comparable to those after morphine application were only observed in EMs (Cmax: 38+/-16 nmol/l; AUC: 173+/-90 nmol x h/l).",Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],173,35425,DB00318,Codeine
,9696456,Cmax,In PMs only traces of morphine could be detected in plasma (Cmax: 2+/-1 nmol/l; AUC: 10+/-7 nmol x h/l).,Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[nM] / [l],2,35426,DB00318,Codeine
,9696456,AUC,In PMs only traces of morphine could be detected in plasma (Cmax: 2+/-1 nmol/l; AUC: 10+/-7 nmol x h/l).,Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696456/),[h·nM] / [l],10,35427,DB00318,Codeine
,15509185,bioavailability,"Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.",Clinical pharmacology of tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,87-95,35613,DB00318,Codeine
,15509185,plasma protein binding,Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.,Clinical pharmacology of tramadol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,20,35614,DB00318,Codeine
,15509185,elimination half-life,The mean elimination half-life is about 6 hours.,Clinical pharmacology of tramadol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),h,6,35615,DB00318,Codeine
,26218586,clearance (CL/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],75,38897,DB00318,Codeine
,26218586,volume of distribution (V/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,756,38898,DB00318,Codeine
,26218586,absorption rate constant (Ka ),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),1/[h],0.581,38899,DB00318,Codeine
,26218586,CL/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38900,DB00318,Codeine
,26218586,V/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,119,38901,DB00318,Codeine
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38902,DB00318,Codeine
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],21,38903,DB00318,Codeine
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,193,38904,DB00318,Codeine
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,174,38905,DB00318,Codeine
,1389934,Cmax,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[ng] / [ml],34 to 38,38910,DB00318,Codeine
,1389934,AUC,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[h·ng] / [ml],208 to 245,38911,DB00318,Codeine
,1389934,tmax,The median tmax of oxycodone was 1 h in all groups.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),h,1,38912,DB00318,Codeine
,1389934,bioavailability,The bioavailability of oral relative to i.m. oxycodone was 60%.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),%,60,38913,DB00318,Codeine
,1389934,renal clearance,The mean renal clearance of oxycodone was 0.07-0.08 l min-1.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[l] / [min],0.07-0.08,38914,DB00318,Codeine
,27779356,CMAX,A single-dose morphine 100 mcg·kg-1 achieved a mean CMAX 10 mcg·l-1 .,Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779356/),[mcg] / [l],10,40886,DB00318,Codeine
,27779356,steady-state concentration,Repeat 4-hourly dosing achieved mean steady-state concentration 13-18 mcg·l-1 ; concentrations associated with good analgesia after intravenous administration.,Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779356/),[mcg] / [l],13-18,40887,DB00318,Codeine
,7742159,minimum plasma concentration,There was a nine-fold variation in the minimum plasma concentration of codeine consistent with pain relief (40-350 ng ml-1).,Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742159/),[ng] / [ml],40-350,41394,DB00318,Codeine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.0,42982,DB00318,Codeine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,5.5,42983,DB00318,Codeine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42984,DB00318,Codeine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.61,42985,DB00318,Codeine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,2.04,42986,DB00318,Codeine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42987,DB00318,Codeine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.88,42988,DB00318,Codeine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],49.2,44070,DB00318,Codeine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],32.6,44071,DB00318,Codeine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],28.4,44072,DB00318,Codeine
,25391549,C(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[ng] / [ml],37.3,44073,DB00318,Codeine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,5.9,44074,DB00318,Codeine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,8.0,44075,DB00318,Codeine
,25391549,t(max),"Mean C(max) values were 49.2, 32.6, and 28.4 ng/mL for the low-, intermediate-, and high-level coating hydrocodone ER tablet prototypes, respectively, and 37.3 ng/mL for the hydrocodone IR/APAP tablet; respective median t(max) values were 5.9, 8.0, 8.0, and 1.0 h.",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),h,1.0,44076,DB00318,Codeine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],640,44077,DB00318,Codeine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],600,44078,DB00318,Codeine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],578,44079,DB00318,Codeine
,25391549,AUC(0-∞),"Total systemic exposure to hydrocodone (AUC(0-∞)) was comparable between hydrocodone ER tablet prototypes (640, 600, and 578 ng·h/mL, respectively) and hydrocodone IR/APAP (581 ng·h/mL).",Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25391549/),[h·ng] / [ml],581,44080,DB00318,Codeine
,24271356,retention times,The retention times were 8.6 min for the internal standard and 11.3 min for codeine.,Determination of codeine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271356/),min,8.6,47675,DB00318,Codeine
,24271356,retention times,The retention times were 8.6 min for the internal standard and 11.3 min for codeine.,Determination of codeine in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271356/),min,11.3,47676,DB00318,Codeine
,1811505,half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,2-4,50213,DB00318,Codeine
,1811505,final half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,9-11,50214,DB00318,Codeine
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,1-6,50215,DB00318,Codeine
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,7-12,50216,DB00318,Codeine
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],14.40,52417,DB00318,Codeine
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],11.54,52418,DB00318,Codeine
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],157.87,52419,DB00318,Codeine
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],106.44,52420,DB00318,Codeine
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.18,52421,DB00318,Codeine
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.15,52422,DB00318,Codeine
,29124988,volume of distribution,"Butalbital is a small molecule (approximately 220 Da), with 26% protein binding, a 0.8 L/kg volume of distribution, and is eliminated nearly 80% unchanged in the urine.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[l] / [kg],0.8,56164,DB00318,Codeine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mg] / [dl],46.4,56165,DB00318,Codeine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mM] / [l],3.4,56166,DB00318,Codeine
,29124988,total body elimination,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),%,60,56167,DB00318,Codeine
,29124988,clearance,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[ml] / [min],233-300,56168,DB00318,Codeine
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.01,58931,DB00318,Codeine
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.51,58932,DB00318,Codeine
,1424423,volume of distribution,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,211.9,58933,DB00318,Codeine
,1424423,total plasma clearance,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[l] / [h],48.6,58934,DB00318,Codeine
,1424423,absolute oral bioavailability,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),%,87,58935,DB00318,Codeine
,1424423,volume of distribution,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,249.1,58936,DB00318,Codeine
,1424423,steady-state concentration,"When administered orally as 10 mg oxycodone hydrochloride every 4 hours, there was no accumulation of oxycodone at steady state and the mean +/- SD steady-state concentration was 34.6 +/- 10.3 micrograms/L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[μg] / [l],34.6,58937,DB00318,Codeine
<,21551257,IC(50),"However, IC(50) values were <100 μM only for UGT2B4, UGT2B7, and UGT2B15.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,100,59703,DB00318,Codeine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,5.8,59704,DB00318,Codeine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,4.6,59705,DB00318,Codeine
,21551257,K(i),"K(i) values for KTM inhibition of MOR 3- and 6-glucuronidation and COD 6-glucuronidation by human liver microsomes supplemented with 2% bovine serum albumin were 5.8 ± 0.1, 4.6 ± 0.2, and 3.5 ± 0.1 μM, respectively.",Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21551257/),μM,3.5,59706,DB00318,Codeine
,26655109,flow rate,"The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.",Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[μl] / [min],300,60351,DB00318,Codeine
,26655109,limit of detection,The limit of detection was 30pg/mL for all analytes.,Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[pg] / [ml],30,60352,DB00318,Codeine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65144,DB00318,Codeine
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65145,DB00318,Codeine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65146,DB00318,Codeine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65147,DB00318,Codeine
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.5,65148,DB00318,Codeine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.4,65149,DB00318,Codeine
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65150,DB00318,Codeine
,26350273,AUC0-t,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],342.9,65151,DB00318,Codeine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],325.3,65152,DB00318,Codeine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],346.3,65153,DB00318,Codeine
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],328.5,65154,DB00318,Codeine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],0.64,65155,DB00318,Codeine
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65156,DB00318,Codeine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65157,DB00318,Codeine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.06,65158,DB00318,Codeine
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.19,65159,DB00318,Codeine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65160,DB00318,Codeine
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,16.1,65161,DB00318,Codeine
,17613029,flow rate,"Ethylcellulose with di-n-butyl-phthalate in ethanol and methylene chloride mixture for the coating of drug resinate beads was performed in Glatt fluidized bed coater, where the coating solution flow rate was 8-12 g/min, the inlet air temperature was 50-60 degrees C, the outlet air temperature was 32-38 degrees C, the atomizing air pressure was 2.0 bar and the fluidized air pressure was adjusted as required.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),[g] / [min],8-12,68225,DB00318,Codeine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,103.6,68226,DB00318,Codeine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,98.1,68227,DB00318,Codeine
,29772054,clearance,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [h·kg],5.2,69115,DB00318,Codeine
,29772054,volume of distribution,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [kg],1.5 and 4.7,69116,DB00318,Codeine
,29772054,area under the curve,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[h·ng] / [ml],17,69117,DB00318,Codeine
,29772054,plasma concentration at 2 minutes,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[ng] / [ml],60,69118,DB00318,Codeine
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,1.3-3.5,69119,DB00318,Codeine
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,2.1,69120,DB00318,Codeine
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB00318,Codeine
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB00318,Codeine
,34268884,absorption fraction,The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake.,Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),,0.31,73655,DB00318,Codeine
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,2,73656,DB00318,Codeine
,34268884,time to maximum concentration ( T max ),"The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06).",Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268884/),h,3,73657,DB00318,Codeine
,3437070,AUC24,"However, accumulation of morphine during multiple dosing was significant (AUC24 = 102 +/- 33 ng/mL/hr after single dose versus 212 +/- 118 ng/mL/hr after the last multiple dose).",Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437070/),[ng] / [h·ml],102,74930,DB00318,Codeine
,3437070,AUC24,"However, accumulation of morphine during multiple dosing was significant (AUC24 = 102 +/- 33 ng/mL/hr after single dose versus 212 +/- 118 ng/mL/hr after the last multiple dose).",Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437070/),[ng] / [h·ml],212,74931,DB00318,Codeine
,1623909,total plasma clearance,Codeine had a medium to high extraction ratio and a total plasma clearance of 10.8 (4.3) ml.min-1.kg-1.,The postoperative pharmacokinetics of codeine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),[ml] / [kg·min],10.8,75152,DB00318,Codeine
,1623909,systemic availability,The systemic availability of codeine varied extensively between subjects (range 12-84%).,The postoperative pharmacokinetics of codeine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),%,12-84,75153,DB00318,Codeine
,15920700,flow rate,"The analytes were separated using a mobile phase, consisting of acetonitrile and phosphate buffer (8:92, v/v) at a flow rate of 1 mL/min, and UV detection at 205 nm.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),[ml] / [min],1,80383,DB00318,Codeine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,14.7,80384,DB00318,Codeine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,13.8,80385,DB00318,Codeine
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,10.2,80386,DB00318,Codeine
,16037150,arterial Pco(2),The median arterial Pco(2) level was 41 mm Hg and the interquartile range was 39-46 mm Hg.,"Preoperative ""fentanyl challenge"" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16037150/),hg·mm,41,80675,DB00318,Codeine
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,151.2,83339,DB00318,Codeine
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,110.0,83340,DB00318,Codeine
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,302.3,83341,DB00318,Codeine
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,199.2,83342,DB00318,Codeine
,25965875,analysis time of,The analysis time of per sample was 1.0min.,Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),min,1.0,83343,DB00318,Codeine
,902456,peak plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],194 to 340,84173,DB00318,Codeine
,902456,peak codeine plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],102 to 140,84174,DB00318,Codeine
,902456,plasma t1/2,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),h,3.32,84175,DB00318,Codeine
,902456,volume of distribution,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[l] / [kg],5.1,84176,DB00318,Codeine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,42,84177,DB00318,Codeine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,53,84178,DB00318,Codeine
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB00318,Codeine
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB00318,Codeine
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB00318,Codeine
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,13.9,86627,DB00318,Codeine
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,3.4,86628,DB00318,Codeine
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],0.26,86629,DB00318,Codeine
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],1.13,86630,DB00318,Codeine
,2046334,half-life,"Following heroin administration, 6-AM was excreted rapidly with an average half-life of 0.6 h.",Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,0.6,87051,DB00318,Codeine
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,3.6,87052,DB00318,Codeine
,2046334,half-life,The average half-life for free morphine was 3.6 h and for total morphine was 7.9 h.,Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046334/),h,7.9,87053,DB00318,Codeine
,19357842,maximal morphine concentration,Thirty subjects (group I) had a mean (standard deviation) maximal morphine concentration of 2.0 (1.0) ng/ml.,The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19357842/),[ng] / [ml],2.0,87239,DB00318,Codeine
,23690065,flow rate,"Following the addition of codeine as an internal standard and simple liquid-liquid extraction with ethyl acetate-isopropanol (95:5, v/v), the analytes were separated on a Zorbax SB-C18 column (4.6 × 150 mm i.d., 5 µm) and eluted with a mobile phase consisting of methanol-10 mmol/L ammonium acetate containing 1% formic acid (50:50, v/v) at a flow rate of 1.0 mL/min.",Method development and validation of olprinone in human plasma by HPLC coupled with ESI-MS-MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23690065/),[ml] / [min],1.0,89138,DB00318,Codeine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],28.6,89264,DB00318,Codeine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],33.4,89265,DB00318,Codeine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],42.4,89266,DB00318,Codeine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],36.5,89267,DB00318,Codeine
,27138027,maximum observed plasma hydrocodone concentration (Cmax ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],31.6,89268,DB00318,Codeine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],565,89269,DB00318,Codeine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],660,89270,DB00318,Codeine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],973,89271,DB00318,Codeine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],983,89272,DB00318,Codeine
,27138027,area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ),"Mean maximum observed plasma hydrocodone concentration (Cmax ) in subjects with normal renal function, mild, moderate, and severe impairment, and end-stage renal disease was 28.6, 33.4, 42.4, 36.5, and 31.6 ng/mL, and mean area under the plasma hydrocodone concentration-versus-time curve from time 0 to infinity (AUC0-∞ ) was 565, 660, 973, 983, and 638 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],638,89273,DB00318,Codeine
,27138027,Cmax,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],10.1,89274,DB00318,Codeine
,27138027,Cmax,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[ng] / [ml],13.0,89275,DB00318,Codeine
,27138027,AUC0-∞,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],155,89276,DB00318,Codeine
,27138027,AUC0-∞,"Mean Cmax with normal hepatic function and moderate impairment was 10.1 and 13.0 ng/mL, and mean AUC0-∞ was 155 and 269 ng·h/mL, respectively.",Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138027/),[h·ng] / [ml],269,89277,DB00318,Codeine
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],4.9,90976,DB00318,Codeine
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],3.1,90977,DB00318,Codeine
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,1.2,90978,DB00318,Codeine
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,5.0,90979,DB00318,Codeine
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91599,DB00318,Codeine
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91600,DB00318,Codeine
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91601,DB00318,Codeine
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91602,DB00318,Codeine
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,2,93414,DB00318,Codeine
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.55,93415,DB00318,Codeine
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.75,93416,DB00318,Codeine
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,0.85,93417,DB00318,Codeine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],12.6,93666,DB00318,Codeine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],20.7,93667,DB00318,Codeine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],30.3,93668,DB00318,Codeine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],41.2,93669,DB00318,Codeine
,25813216,C max,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[ng] / [ml],62.5,93670,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],199,93671,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],38,93672,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],2,93673,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],592,93674,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],766,93675,DB00318,Codeine
,25813216,AUC∞,"The mean C max was 12.6, 20.7, 30.3, 41.2, and 62.5 ng/mL and the mean AUC∞ was 199, 382, 592, 766, and 1189 ng.h/mL for hydrocodone ER 15, 30, 45, 60, and 90 mg, respectively.",Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813216/),[h·ng] / [ml],1189,93676,DB00318,Codeine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],57-110,93726,DB00318,Codeine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],23-54,93727,DB00318,Codeine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],3.9-14,93728,DB00318,Codeine
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],1.7-15,93729,DB00318,Codeine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,2-30,93730,DB00318,Codeine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,30-480,93731,DB00318,Codeine
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,60-360,93732,DB00318,Codeine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,124-208,93733,DB00318,Codeine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,162-227,93734,DB00318,Codeine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,73-234,93735,DB00318,Codeine
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,80-246,93736,DB00318,Codeine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],5037-8954,93737,DB00318,Codeine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],3084-5524,93738,DB00318,Codeine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],1444-5560,93739,DB00318,Codeine
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],692-3843,93740,DB00318,Codeine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.47-0.84,93741,DB00318,Codeine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.22-0.84,93742,DB00318,Codeine
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.10-0.58,93743,DB00318,Codeine
,3741728,elimination t1/2,Codeine was absorbed and eliminated relatively rapidly [elimination t1/2 = 2.3 +/- 0.4 h (mean +/- s.d.)].,Comparative disposition of codeine and pholcodine in man after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741728/),h,2.3,94225,DB00318,Codeine
,3741728,"t1/2,z","While codeine kinetics were adequately described by a one-compartment open model with first-order absorption, a two-compartment model was required to describe pholcodine elimination from plasma (t1/2,z = 37.0 +/- 4.2 h).",Comparative disposition of codeine and pholcodine in man after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741728/),h,37.0,94226,DB00318,Codeine
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),min,37,96178,DB00318,Codeine
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),h,6.2,96179,DB00318,Codeine
,8971431,bioavailable,Two 10 mg tablets of oral CR oxycodone hydrochloride were 102.7% bioavailable relative to 20 mg of IR oxycodone hydrochloride oral solution.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),%,102.7,96180,DB00318,Codeine
,26032168,plasma Tmax,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼2,98635,DB00318,Codeine
,26032168,t1/2,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼10,98636,DB00318,Codeine
,26032168,elimination t1/2,"During washout, quinine urinary concentrations steadily declined (elimination t1/2 ∼16 hours), with a 94% decrease observed 72 hours postdose.",Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼16,98637,DB00318,Codeine
,8227477,time to reach maximum peak plasma concentration (tmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.0,98872,DB00318,Codeine
,8227477,time to reach maximum peak plasma concentration (tmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.4,98873,DB00318,Codeine
,8227477,maximum peak plasma concentration (Cmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[ng] / [ml],172,98874,DB00318,Codeine
,8227477,maximum peak plasma concentration (Cmax),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[ng] / [ml],225,98875,DB00318,Codeine
,8227477,area under the curve (AUC infinity),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[h·ng] / [ml],590,98876,DB00318,Codeine
,8227477,area under the curve (AUC infinity),"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[h·ng] / [ml],779,98877,DB00318,Codeine
,8227477,Cl/F,"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[l] / [h],104,98878,DB00318,Codeine
,8227477,Cl/F,"No significant differences were observed in time to reach maximum peak plasma concentration (tmax) (1.0 +/- 0.4 versus 1.4 +/- 1.0 hours), maximum peak plasma concentration (Cmax) (172 +/- 25 versus 225 +/- 97 ng/mL), area under the curve (AUC infinity) (590 +/- 96 versus 779 +/- 234 ng*h/mL), and Cl/F (104 +/- 17 versus 89 +/- 27 L/h) between SCPs and HCs.",Codeine disposition in sickle cell patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),[l] / [h],89,98879,DB00318,Codeine
,8227477,mean residence time (MRT),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,3.7,98880,DB00318,Codeine
,8227477,mean residence time (MRT),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,4.7,98881,DB00318,Codeine
,8227477,half-life (t1/2),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,1.7,98882,DB00318,Codeine
,8227477,half-life (t1/2),"Conversely, significant differences were observed in mean residence time (MRT) (3.7 +/- 0.3 versus 4.7 +/- 0.3 hours) and half-life (t1/2) (1.7 +/- 0.2 versus 2.8 +/- 0.3 hours).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),h,2.8,98883,DB00318,Codeine
,8227477,plasma protein binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,66.0,98884,DB00318,Codeine
,8227477,plasma protein binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,30.5,98885,DB00318,Codeine
,8227477,binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,68.4,98886,DB00318,Codeine
,8227477,binding,"In a separate study, significant differences were observed in the in vitro plasma protein binding of codeine in SCPs (66.0 +/- 8.6%) and HCs (30.5 +/- 2.7%) as well as in vivo binding (68.4 +/- 11.1% for SCPs versus 29.2 +/- 3.4% for HCs).",Codeine disposition in sickle cell patients compared with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227477/),%,29.2,98887,DB00318,Codeine
<,30248201,clearance,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),[ml] / [kg·min],1,99196,DB00318,Codeine
,30248201,milk-to-plasma concentration ratio,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),,1,99197,DB00318,Codeine
,22448718,half-life,"Maternal plasma oxycodone concentration decreased with a median half-life of 2.6 hr (range, 1.8-2.8).",Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22448718/),h,2.6,99803,DB00318,Codeine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,8.5,101982,DB00318,Codeine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,7.0,101983,DB00318,Codeine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,11.5,101984,DB00318,Codeine
,9010701,peak change,"Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,15.5,101985,DB00318,Codeine
,9010701,peak change,"Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,5.5,101986,DB00318,Codeine
,9010701,peak change,"Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort.","Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010701/),mm,10,101987,DB00318,Codeine
,24887324,peak concentration,"For the 19 subjects who completed the study, morphine concentrations ranged from <300 to 7522 μg/L with a median peak concentration of 5239 μg/L.",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],5239,103153,DB00318,Codeine
,24887324,peak concentrations,"No specimens were positive for codeine at a cutoff concentration of 2000 μg/L, but 20.2% exceeded 300 μg/L, with peak concentrations of 658 μg/L (284-1540).",Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887324/),[μg] / [l],658,103154,DB00318,Codeine
,9587953,AUC ratios of brain to blood,"The AUC ratios of brain to blood were 0.99 +/- 0.25 and 0.95 +/- 0.16 for Dose 1 and 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,0.99,103215,DB00318,Codeine
,9587953,AUC ratios of brain to blood,"The AUC ratios of brain to blood were 0.99 +/- 0.25 and 0.95 +/- 0.16 for Dose 1 and 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,0.95,103216,DB00318,Codeine
,9587953,Css ratio of brain to blood,The Css ratio of brain to blood was 1.06 +/- 0.12 for the exponential infusion.,Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,1.06,103217,DB00318,Codeine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,25,103218,DB00318,Codeine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,22,103219,DB00318,Codeine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,27,103220,DB00318,Codeine
,9587953,half-lives,"The half-lives were 25 +/- 4 min, 22 +/- 2 min in blood and 27 +/- 5 min, 25 +/- 5 min in brain for Dose 1 and Dose 2, respectively.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),min,25,103221,DB00318,Codeine
,9587953,unbound AUCblood,"Codeine was demethylated to morphine with an unbound AUCblood,morphine/AUCblood,codeine ratio of 7.7 +/- 5.1% in blood.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,7,103222,DB00318,Codeine
,9587953,"morphine/AUCblood,","Codeine was demethylated to morphine with an unbound AUCblood,morphine/AUCblood,codeine ratio of 7.7 +/- 5.1% in blood.",Blood-brain barrier equilibration of codeine in rats studied with microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587953/),,7,103223,DB00318,Codeine
,17978495,V(d),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,226.7,103671,DB00318,Codeine
,17978495,CL,"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],37.9,103672,DB00318,Codeine
,17978495,t(1/2),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,4.1,103673,DB00318,Codeine
,17978495,V(d),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,276.8,103674,DB00318,Codeine
,17978495,CL,"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],95.1,103675,DB00318,Codeine
,17978495,t(1/2),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,2.0,103676,DB00318,Codeine
,1981718,weight normalized volume of distribution of (Vdarea),"The weight normalized volume of distribution of (Vdarea) and total body clearance (CL) were 5.1 +/- 1.7 liters/kg and 6.2 +/- 1.5 liters/kg/hr, respectively.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),[l] / [kg],5.1,106293,DB00318,Codeine
,1981718,total body clearance (CL),"The weight normalized volume of distribution of (Vdarea) and total body clearance (CL) were 5.1 +/- 1.7 liters/kg and 6.2 +/- 1.5 liters/kg/hr, respectively.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),[l] / [h·kg],6.2,106294,DB00318,Codeine
,1981718,Mean residence time,Mean residence time of codeine averaged 34.1 +/- 6.9 minutes.,Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),min,34.1,106295,DB00318,Codeine
,1981718,ratio of AUCmorphine/AUCcodeine,The ratio of AUCmorphine/AUCcodeine was 0.05 +/- 0.02.,Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),,0.05,106296,DB00318,Codeine
,1981718,absolute bioavailability,"The absolute bioavailability of codeine calculated was 8.3 +/- 3.2%, indicating extensive first pass metabolism of codeine.",Pharmacokinetics of codeine after parenteral and oral dosing in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981718/),%,8.3,106297,DB00318,Codeine
,9187531,maximum daily dosage,"The maximum daily dosage is 90mg, and the maximum duration of treatment is 48 hours.",Ketorolac for postoperative pain management in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187531/),,90,112027,DB00318,Codeine
,8706777,Free concentrations,"Free concentrations of quinidine were 11-times lower in cerebrospinal fluid than in plasma, and ranged from 9-15 nmol.l-1.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9-15,112338,DB00318,Codeine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],1.45,112339,DB00318,Codeine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],9.86,112340,DB00318,Codeine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],0.23,112341,DB00318,Codeine
,8706777,concentrations,"Morphine concentrations were significantly lower in patients pre-treated with quinidine, both in plasma (median 1.45 nmol.l-1, range 0.74-1.95 nmol.l-1 vs 9.86 nmol.l-1, range 4.59-28.4 nmol.l-1) and in cerebrospinal fluid (0.23, 0.16-0.61 nmol.l-1 vs 3.63, 0.6-8.09 nmol.l-1).",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),[nM] / [l],3.63,112342,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,3.07 x 10 (,112343,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,1.68-3.68 x 10 (-3,112344,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,19.87 x 10 (-3),112345,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,9.87-66.22 x 10 (,112346,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),-3·10·d,0.83,112347,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,0.58-1.45 x 10 (,112348,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,7.19 x 10 (-3),112349,DB00318,Codeine
,8706777,concentration ratio,"The morphine/codeine concentration ratio in plasma (3.07 x 10 (-3), 1.68-3.68 x 10 (-3) vs 19.87 x 10 (-3), 9.87-66.22 x 10 (-3) and in cerebrospinal fluid (0.83 d 10 (-3), 0.58-1.45 x 10 (-3) vs 7.19 x 10 (-3), 2.03-17.7 x 10 (-3) was also lower.",Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706777/),,2.03-17.7 x 10 (-3,112350,DB00318,Codeine
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],159,113220,DB00318,Codeine
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],138,113221,DB00318,Codeine
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.9,113222,DB00318,Codeine
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.4,113223,DB00318,Codeine
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],6.8,113224,DB00318,Codeine
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],7.4,113225,DB00318,Codeine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.35 to 0.42,120652,DB00318,Codeine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.06-0.08,120653,DB00318,Codeine
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0,120654,DB00318,Codeine
,9062618,plasma clearance,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [min],0.83,121549,DB00318,Codeine
,9062618,volume of distribution at steady-state,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [kg],2.02,121550,DB00318,Codeine
,9062618,terminal elimination half-life,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),min,157,121551,DB00318,Codeine
,9062618,peak plasma concentration,"After intranasal administration, peak plasma concentration of oxycodone was 13 +/- 6 ng/ml and it was reached in the median time of 25 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[ng] / [ml],13,121552,DB00318,Codeine
,9062618,bioavailability,The intranasal bioavailability of oxycodone was 0.46 +/- 0.34.,Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),,0.46,121553,DB00318,Codeine
above,1623695,area under the plasma concentration-time curves,Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration-time curves above 550 ng.,Treatment of opioid-induced constipation with oral naloxone: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623695/),ng,550,121859,DB00318,Codeine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,10,122047,DB00318,Codeine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,25,122048,DB00318,Codeine
,8149873,Bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,8,122049,DB00318,Codeine
,8149873,bioavailability,"Bioavailability of codeine using the dosed feed route increased with dose, varying from 10% to 25%, which was somewhat higher than the previously reported approximately 8% bioavailability using the gavage route.",Codeine toxicokinetics in rats during a two-year dosed feed study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149873/),%,8,122050,DB00318,Codeine
,3190994,tmax,"4. After the single doses, pholcodine was absorbed rapidly (tmax = 1.6 +/- 1.2 h) and eliminated slowly with a mean half-life of 50.1 +/- 4.1 h.",Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),h,1.6,125695,DB00318,Codeine
,3190994,half-life,"4. After the single doses, pholcodine was absorbed rapidly (tmax = 1.6 +/- 1.2 h) and eliminated slowly with a mean half-life of 50.1 +/- 4.1 h.",Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),h,50.1,125696,DB00318,Codeine
,3190994,renal clearance,The renal clearance of pholcodine was 137 +/- 34 ml min-1 and was inversely correlated with urine pH (r = 0.60) but not with urine flow rate.,Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),[ml] / [min],137,125697,DB00318,Codeine
,3190994,plasma protein binding,The plasma protein binding was 23.5%.,Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190994/),%,23.5,125698,DB00318,Codeine
,17876144,CL/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),[l] / [h],45.6,126541,DB00318,Codeine
,17876144,Vd/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),l,473.0,126542,DB00318,Codeine
,17876144,t(1/2),"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,7.2,126543,DB00318,Codeine
,17876144,kel,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,0.103,126544,DB00318,Codeine
,17876144,kal,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,1.082,126545,DB00318,Codeine
,17876144,Lag time,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,0.9 9,126546,DB00318,Codeine
,17876144,lag time,"Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,1,126547,DB00318,Codeine
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,0.34,127614,DB00318,Codeine
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,6.3,127615,DB00318,Codeine
,3438223,time to reach the maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),min,65,127616,DB00318,Codeine
,8934303,detection time,The detection time in the EMIT screening assay was found to be 20-39 h after the 25-mg dose and 30-52 h after the 50-mg dose.,Urine and plasma pharmacokinetics of codeine in healthy volunteers: implications for drugs-of-abuse testing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8934303/),h,20-39,129236,DB00318,Codeine
,8934303,detection time,The detection time in the EMIT screening assay was found to be 20-39 h after the 25-mg dose and 30-52 h after the 50-mg dose.,Urine and plasma pharmacokinetics of codeine in healthy volunteers: implications for drugs-of-abuse testing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8934303/),h,30-52,129237,DB00318,Codeine
,23098635,CMAX,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],11.73,129788,DB00318,Codeine
,23098635,terminal half-life,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,1.60,129789,DB00318,Codeine
,23098635,CMAX,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],5.2,129790,DB00318,Codeine
,23098635,terminal half-life,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,3.07,129791,DB00318,Codeine
,21899209,flow rate,"An isocratic mobile phase consisting of acetonitrile-0.1% trifluoroacetic acid (TFA)-water (12:40:48, v/v/v), was run at a flow rate of 1.0 mL/min.",A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),[ml] / [min],1.0,130256,DB00318,Codeine
,21899209,Recoveries,Recoveries were 76.10-83.81% with coefficients of variation of 1.86-6.93%.,A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),%,76.10-83.81,130257,DB00318,Codeine
,27558774,MEC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],31.5,130960,DB00318,Codeine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],74.1,130961,DB00318,Codeine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],63.4,130962,DB00318,Codeine
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],76.1,130963,DB00318,Codeine
,27558774,MEAC,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],75,130964,DB00318,Codeine
,27558774,analgesic potency,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],60,130965,DB00318,Codeine
,11824817,run time,The run time was 4 min.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),min,4,130987,DB00318,Codeine
,11824817,limit of quant,The limit of quantitation was 5.8 ng/ml using 0.5 ml of plasma.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),[ng] / [ml],5.8,130988,DB00318,Codeine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,75.6,131358,DB00318,Codeine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,37.4,131359,DB00318,Codeine
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,18.2,131360,DB00318,Codeine
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00318,Codeine
,22201184,elimination clearance,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),[l] / [h],51.0,132389,DB00318,Codeine
,22201184,volume of the central compartment,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,134,132390,DB00318,Codeine
,22201184,volume of distribution at steady state,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,258,132391,DB00318,Codeine
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,3.8,132392,DB00318,Codeine
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,4.6,132393,DB00318,Codeine
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.8,133621,DB00318,Codeine
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.0,133622,DB00318,Codeine
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.3,135230,DB00318,Codeine
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.1,135231,DB00318,Codeine
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.3,135232,DB00318,Codeine
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.7,135233,DB00318,Codeine
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],451,135234,DB00318,Codeine
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],343,135235,DB00318,Codeine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,573,135236,DB00318,Codeine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,261,135237,DB00318,Codeine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,37.7,135238,DB00318,Codeine
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,14.4,135239,DB00318,Codeine
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,6.3,135240,DB00318,Codeine
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,1.8,135241,DB00318,Codeine
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],20.5,135242,DB00318,Codeine
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],29.7,135243,DB00318,Codeine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,1.47,135547,DB00318,Codeine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,2.75,135548,DB00318,Codeine
,1391681,half-life,"The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h.",Pharmacokinetics and metabolism of codeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),h,1.71,135549,DB00318,Codeine
,1391681,systemic clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],2280,135550,DB00318,Codeine
,1391681,renal clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],93.8,135551,DB00318,Codeine
,1391681,renal clearance,"The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1.",Pharmacokinetics and metabolism of codeine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),[ml] / [min],122,135552,DB00318,Codeine
,1391681,Protein binding,"Protein binding of codeine and codeine-6-glucuronide in vivo was 56.1 +/- 2.5 per cent and 34.0 +/- 3.6 per cent, respectively.",Pharmacokinetics and metabolism of codeine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,56.1,135553,DB00318,Codeine
,1391681,Protein binding,"Protein binding of codeine and codeine-6-glucuronide in vivo was 56.1 +/- 2.5 per cent and 34.0 +/- 3.6 per cent, respectively.",Pharmacokinetics and metabolism of codeine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,34.0,135554,DB00318,Codeine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,23.5,135555,DB00318,Codeine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,46.5,135556,DB00318,Codeine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,23.5,135557,DB00318,Codeine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,27.0,135558,DB00318,Codeine
,1391681,protein binding,"The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.",Pharmacokinetics and metabolism of codeine in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1391681/),%,36.7,135559,DB00318,Codeine
,23879213,Pain levels,Pain levels before treatment averaged 9.5 ± 0.9 out of 10.,A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879213/),,9.5,135573,DB00318,Codeine
,19156643,mass-to-charge ratio (m/z),"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,300/165,135797,DB00318,Codeine
,19156643,m/z,"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,286,135798,DB00318,Codeine
,19156643,linear dynamic,"The method exhibited a linear dynamic range of 0.2-100/0.5-250 ng/mL for codeine/morphine in human plasma, respectively.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2-100,135799,DB00318,Codeine
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2,135800,DB00318,Codeine
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.5,135801,DB00318,Codeine
,19156643,run time,A run time of 2.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),min,2.0,135802,DB00318,Codeine
,10933520,flow rate,"The isocratic elution is performed with methanol-0.01 M oxalic acid, pH 3.0 (30:70, v/v) at a flow rate of 0.95 ml min, using a Silasorb C8 analytical column, 250 x 4 mm, 10 microm.",A rapid high performance liquid chromatographic (HPLC) assay for the determination of oxytetracycline in commercial pharmaceuticals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933520/),min·ml,0.95,141074,DB00318,Codeine
,10933520,Total analysis time,Total analysis time was approximately 7 min.,A rapid high performance liquid chromatographic (HPLC) assay for the determination of oxytetracycline in commercial pharmaceuticals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933520/),min,7,141075,DB00318,Codeine
,6628531,half-lives,The mean half-lives varied between 3.3 h-4.5 h.,Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),h,3.3,141488,DB00318,Codeine
,6628531,half-lives,The mean half-lives varied between 3.3 h-4.5 h.,Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),h,4.5,141489,DB00318,Codeine
,6628531,bioavailability,"From the AUC, the mean bioavailability of orally administered drug was 21% (range 12-34%).",Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628531/),%,21,141490,DB00318,Codeine
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,30,142770,DB00318,Codeine
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,90,142771,DB00318,Codeine
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,54.8,144079,DB00318,Codeine
,7173046,bioavailability,"The relative codeine bioavailability in these groups was 54.8 +/- 4.9 percent and 50.2 +/- 2.1 percent (mean +/- SE), respectively.",An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173046/),%,50.2,144080,DB00318,Codeine
,15650985,t(1/2),The median t(1/2) of oxycodone varied from 5.1 to 5.9 hours.,Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,5.1 to 5.9,144396,DB00318,Codeine
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,3.8,144397,DB00318,Codeine
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,7.0,144398,DB00318,Codeine
,21472729,K(i),Oxycodone competitively inhibited DPHM uptake with a K(i) value of 106 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,106,145692,DB00318,Codeine
,21472729,K(i),DPHM also competitively inhibited oxycodone uptake with a K(i) value of 34.7 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,34.7,145693,DB00318,Codeine
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB00318,Codeine
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB00318,Codeine
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB00318,Codeine
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB00318,Codeine
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB00318,Codeine
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB00318,Codeine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.75,149218,DB00318,Codeine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.6,149219,DB00318,Codeine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,4.4,149220,DB00318,Codeine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,3.73,149221,DB00318,Codeine
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.1,151088,DB00318,Codeine
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.6,151089,DB00318,Codeine
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,3.2,151090,DB00318,Codeine
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,1.4,151091,DB00318,Codeine
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],103.6,151092,DB00318,Codeine
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],99.0,151093,DB00318,Codeine
better,9234868,recovery,After addition of ethylmorphine as internal standard the plasma samples were extracted using C18 ODS-2 solid-phase columns with a recovery better than 80%.,High-performance liquid chromatographic monitoring of intravenously administered diacetylmorphine and morphine and their metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234868/),%,80,158273,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,0.57,158407,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,0.96,158408,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),ng,1.93,158409,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.15,158410,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.28,158411,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.49,158412,DB00318,Codeine
,8820417,concentrations,"The mean concentrations of codeine in hair for the 10, 20, 40, and 60 mg/kg/day groups were 0.29, 0.57, 0.96, and 1.93 ng/mg hair, respectively, and the concentrations of morphine were 0.15, 0.28, 0.49, and 0.79 ng/mg hair, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [mg],0.79,158413,DB00318,Codeine
,8820417,Peak plasma codeine concentrations,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [ml·plasma],"1,441",158414,DB00318,Codeine
,8820417,Peak plasma codeine concentrations,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng] / [ml·plasma],"2,452",158415,DB00318,Codeine
,8820417,areas under the plasma concentration vs. time curve,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng-hr] / [ml],699,158416,DB00318,Codeine
,8820417,areas under the plasma concentration vs. time curve,"Peak plasma codeine concentrations for the 20 and 40 mg/kg groups were 1,441 and 2,452 ng/ml plasma, respectively, and the areas under the plasma concentration vs. time curve were 699 and 1,581 ng-hr/ml, respectively.",Dose-related distribution of codeine and its metabolites into rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820417/),[ng-hr] / [ml],"1,581",158417,DB00318,Codeine
more,18520605,extraction recoveries,"The extraction recoveries were more than 85%, the intraday and interday coefficients of variation were <15%, and the accuracy was >90% for all analytes at relevant plasma concentrations.","Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520605/),%,85,162078,DB00318,Codeine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],11.25,162701,DB00318,Codeine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.6,162702,DB00318,Codeine
,2414066,Peak paracetamol plasma concentrations,"Peak paracetamol plasma concentrations were 11.25 +/- 1.74 micrograms/ml at 0.5 hours, 9.6 +/- 1.04 micrograms/ml at 0.75 hours, and 9.53 +/- 1.66 micrograms/ml at 0.5 hours, respectively, after the standard formulation, the combination without docusate, and paracetamol alone.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[μg] / [ml],9.53,162703,DB00318,Codeine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.83,162704,DB00318,Codeine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,1.92,162705,DB00318,Codeine
,2414066,elimination half-lives,"Mean elimination half-lives for paracetamol were 2.83 +/- 0.51, 1.92 +/- 0.20 and 2.49 +/- 0.46 hours, respectively, and the differences were not significant.","The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),h,2.49,162706,DB00318,Codeine
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],42.1,162707,DB00318,Codeine
,2414066,Peak codeine plasma concentrations,Peak codeine plasma concentrations after the standard formulation were 42.1 +/- 9.4 ng/ml at 0.75 hours compared with 36.9 +/- 3.4 ng/ml at 1.5 hours after the combination without docusate.,"The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2414066/),[ng] / [ml],36.9,162708,DB00318,Codeine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB00318,Codeine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],17.6,164365,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],21.9,164366,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],25.9,164367,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],31.6,164368,DB00318,Codeine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],210.7,164369,DB00318,Codeine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],271.6,164370,DB00318,Codeine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],299.5,164371,DB00318,Codeine
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],493.5,164372,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.6,164373,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.8,164374,DB00318,Codeine
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],13.1,164375,DB00318,Codeine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],105.7,164376,DB00318,Codeine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],134.7,164377,DB00318,Codeine
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],218.0,164378,DB00318,Codeine
,26689716,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) with the mobile phase of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.4 mL/min.",UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),[ml] / [min],0.4,165624,DB00318,Codeine
,26689716,overall run time,The overall run time was 4.0 min.,UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),min,4.0,165625,DB00318,Codeine
,1867958,Cmax,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],445,166872,DB00318,Codeine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1660,166873,DB00318,Codeine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],292,166874,DB00318,Codeine
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1010,166875,DB00318,Codeine
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,0.79,166876,DB00318,Codeine
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1.42,166877,DB00318,Codeine
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,82.2,166878,DB00318,Codeine
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,84.4,166879,DB00318,Codeine
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,5.7,166880,DB00318,Codeine
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,3.3,166881,DB00318,Codeine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1:9,166882,DB00318,Codeine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,35:1,166883,DB00318,Codeine
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,4:1,166884,DB00318,Codeine
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00318,Codeine
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00318,Codeine
,10997932,V(max),The formation of codeine-6-glucuronide exhibited single enzyme Michaelis-Menten kinetics with an average V(max) of 93.6 +/- 35.3 pmol/mg/min.,In vitro interaction of codeine and diclofenac. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),[pM] / [mg·min],93.6,167800,DB00318,Codeine
,10997932,K(i),A noncompetitive inhibition of codeine-6-glucuronidation by diclofenac was observed with an average K(i) of 7.9 microM.,In vitro interaction of codeine and diclofenac. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997932/),μM,7.9,167801,DB00318,Codeine
,16819548,AUC,Significant differences between the EM and UM groups were detected in areas under the plasma concentration versus time curves (AUCs) of morphine with a median (range) AUC of 11 (5-17) microg h l(-1) in EMs and 16 (10-24) microg h l(-1) in UM (P=0.02).,Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),[h·μg] / [l],11,170087,DB00318,Codeine
,16819548,AUC,Significant differences between the EM and UM groups were detected in areas under the plasma concentration versus time curves (AUCs) of morphine with a median (range) AUC of 11 (5-17) microg h l(-1) in EMs and 16 (10-24) microg h l(-1) in UM (P=0.02).,Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),[h·μg] / [l],16,170088,DB00318,Codeine
,16819548,metabolic ratios,"In urine collected over 12 h, the metabolic ratios of the codeine+codeine-6-glucuronide divided by the sum of morphine+its glucuronides metabolites were 11 (6-17) in EMs and 9 (6-16) in UM (P=0.05).",Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),,11,170089,DB00318,Codeine
,16819548,metabolic ratios,"In urine collected over 12 h, the metabolic ratios of the codeine+codeine-6-glucuronide divided by the sum of morphine+its glucuronides metabolites were 11 (6-17) in EMs and 9 (6-16) in UM (P=0.05).",Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819548/),,9,170090,DB00318,Codeine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],6.24,172847,DB00318,Codeine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],8.60,172848,DB00318,Codeine
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],69.6,172849,DB00318,Codeine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2400-8000,174308,DB00318,Codeine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],4200,174309,DB00318,Codeine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2700-7900,174310,DB00318,Codeine
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],5500,174311,DB00318,Codeine
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.4-39,174312,DB00318,Codeine
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.5-42,174313,DB00318,Codeine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,104-251,174314,DB00318,Codeine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,140,174315,DB00318,Codeine
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,110-190,174316,DB00318,Codeine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],473.49,175280,DB00318,Codeine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],491.22,175281,DB00318,Codeine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],488.89,175282,DB00318,Codeine
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],502.28,175283,DB00318,Codeine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.91,175284,DB00318,Codeine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],35.73,175285,DB00318,Codeine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.46,175286,DB00318,Codeine
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],40.45,175287,DB00318,Codeine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],539.93,175288,DB00318,Codeine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],522.45,175289,DB00318,Codeine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],520.10,175290,DB00318,Codeine
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],523.37,175291,DB00318,Codeine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],62.01,175292,DB00318,Codeine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.62,175293,DB00318,Codeine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],61.95,175294,DB00318,Codeine
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.55,175295,DB00318,Codeine
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],22.6,175296,DB00318,Codeine
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],24.0,175297,DB00318,Codeine
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.6,176468,DB00318,Codeine
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.7,176469,DB00318,Codeine
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.2,176470,DB00318,Codeine
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.0,176471,DB00318,Codeine
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,1.8,176472,DB00318,Codeine
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,4.3,176473,DB00318,Codeine
,15692141,maximum APAP concentration ([APAP](max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg] / [ml],71.8,186083,DB00318,Codeine
,15692141,time to peak [APAP] (t(max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.71,186084,DB00318,Codeine
,15692141,area under the receiver operating characteristic curve (AUC(0-8)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],318.3,186085,DB00318,Codeine
,15692141,t(max),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.90,186086,DB00318,Codeine
,15692141,AUC(0-8),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],297.7,186087,DB00318,Codeine
,15692141,t(max),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,2.87,186088,DB00318,Codeine
,15692141,AUC(0-8),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],232.1,186089,DB00318,Codeine
,31597014,absorption lag,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),h,0.23,187251,DB00318,Codeine
,31597014,absorption rate constant (kaCR,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.19,187252,DB00318,Codeine
,31597014,kaSOL,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.94,187253,DB00318,Codeine
,31597014,half-life,Effects on pupil diameter were delayed relative to plasma (14 minutes half-life) for all formulations and were best described by a proportional Emax model.,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),min,14,187254,DB00318,Codeine
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],31.1,187255,DB00318,Codeine
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],52.8,187256,DB00318,Codeine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],17.1,188412,DB00318,Codeine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],15.5,188413,DB00318,Codeine
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],22.2,188414,DB00318,Codeine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,1.0,188415,DB00318,Codeine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,2.0,188416,DB00318,Codeine
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,3.0,188417,DB00318,Codeine
,22451244,Clearance,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),[l] / [h],28.9,189233,DB00318,Codeine
,22451244,volume of distribution at steady state,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),l,186,189234,DB00318,Codeine
,22451244,half-life of elimination,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),h,5.2,189235,DB00318,Codeine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,59,189236,DB00318,Codeine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,64,189237,DB00318,Codeine
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,55,189238,DB00318,Codeine
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189673,DB00318,Codeine
,1804656,AUC,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189674,DB00318,Codeine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],2.2,189675,DB00318,Codeine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],0.81,189676,DB00318,Codeine
,1804656,CLR,"After codeine alone, the t1/2 (h), AUC (mumol.l-1.h) and CLR (ml.min-1) for codeine were 2.2, 0.81, and 252 respectively.",Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804656/),[ml] / [min],252,189677,DB00318,Codeine
below,18334103,Mor/Cod,The Mor/Cod in plasma were below 1 for both UMs and EMs during the first 12 h.,CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189803,DB00318,Codeine
>,18334103,ratios,"After 12 h, 9% of the 11 UM and none of the 12 EM had ratios > 1.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189804,DB00318,Codeine
below,18334103,Mor/Cod ratios,"In urine, Mor/Cod ratios were below one for all EMs and UMs during the first 12 h.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,one,189805,DB00318,Codeine
>,18334103,Mor/Cod ratios,"Thus, CYP2D6 genotyping in general will not explain Mor/Cod ratios > 1 in plasma or urine, unless the time of drug intake is more than 24 h previous.",CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18334103/),,1,189806,DB00318,Codeine
,1867957,area under the curve (AUC),"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[h·nM] / [l],1020,190000,DB00318,Codeine
,1867957,half-life,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),h,2.58,190001,DB00318,Codeine
,1867957,total plasma clearance,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[l] / [h·kg],2.02,190002,DB00318,Codeine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],214.2,190750,DB00318,Codeine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],474.3,190751,DB00318,Codeine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],638.4,190752,DB00318,Codeine
,12194925,peak codeine concentrations,Mean (SE) peak codeine concentrations were 214.2 +/- 27.6 and 474.3 +/- 77.0 micro g/L in plasma and 638.4 +/- 64.4 and 1599.3 +/- 241.0 micro g/L in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),[μg] / [l],1599.3,190753,DB00318,Codeine
,12194925,oral fluid-to-plasma ratio,The oral fluid-to-plasma ratio for codeine was relatively constant ( approximately 4) from 1 to 12 h.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),,4,190754,DB00318,Codeine
,12194925,half-life (t(1/2)),The mean half-life (t(1/2)) of codeine was 2.2 +/- 0.10 h in plasma and 2.2 +/- 0.16 h in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,2.2,190755,DB00318,Codeine
,12194925,half-life (t(1/2)),The mean half-life (t(1/2)) of codeine was 2.2 +/- 0.10 h in plasma and 2.2 +/- 0.16 h in oral fluid.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,2.2,190756,DB00318,Codeine
,12194925,oral fluid detection time,"Mean codeine oral fluid detection time was 21 h with a 2.5 microg/L cutoff, longer than that of plasma (12-16 h).",Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,21,190757,DB00318,Codeine
,12194925,oral fluid detection time,"Mean codeine oral fluid detection time was 21 h with a 2.5 microg/L cutoff, longer than that of plasma (12-16 h).",Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,12-16,190758,DB00318,Codeine
,12194925,Detection times,Detection times with the proposed Substance Abuse and Mental Health Services Administration cutoff (40 microg/L) were only 7 h.,Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194925/),h,7,190759,DB00318,Codeine
,7735464,recoveries,"The method had good reproducibility, precision, accuracy and recoveries of 91 and 90% for codeine and nalorphine, respectively.",Determination of codeine in human plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735464/),%,91,191173,DB00318,Codeine
,7735464,recoveries,"The method had good reproducibility, precision, accuracy and recoveries of 91 and 90% for codeine and nalorphine, respectively.",Determination of codeine in human plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735464/),%,90,191174,DB00318,Codeine
,7605420,drug clearance,2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[ml] / [kg·min],15.2,192431,DB00318,Codeine
,7605420,volume of distribution (Vss),2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[l] / [kg],2.1,192432,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,0.,193259,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,0.51,193260,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),ng,14.46,193261,DB00318,Codeine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],0.67,193262,DB00318,Codeine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],1.04,193263,DB00318,Codeine
,8801066,glucuronide,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],13.80,193264,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],0.67,193265,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],1.04,193266,DB00318,Codeine
,8801066,concentrations,"Codeine concentrations in the hair of SD, DA, and pigmented LE hair were 0.98 +/- 0.10, 5.99 +/- 1.24, and 111.93 +/- 18.69 ng/mg hair, respectively; morphine concentrations were 0.34 +/- 0.04, 0.51 +/- 0.11, and 14.46 +/- 1.81 ng/mg hair, respectively; morphine glucuronide concentrations were 0.67 +/- 0.08, 1.04 +/- 0.37, and 13.80 +/- 3.60 ng/mg hair, respectively.",Incorporation of codeine and metabolites into hair. Role of pigmentation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801066/),[ng] / [mg],13.80,193267,DB00318,Codeine
,11043656,t(1/2),"As a result, the t(1/2) for the acidic method was significantly less than that of the control method (1.8 vs. 3.0 h, respectively).",The effects of collection methods on oral fluid codeine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043656/),h,1.8,193476,DB00318,Codeine
,11043656,t(1/2),"As a result, the t(1/2) for the acidic method was significantly less than that of the control method (1.8 vs. 3.0 h, respectively).",The effects of collection methods on oral fluid codeine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043656/),h,3.0,193477,DB00318,Codeine
,3171947,urinary recovery,"With each preparation, the mean urinary recovery of dihydrocodeine was approximately 30 mg, and both had a comparable bioavailability.",Two assays for dihydrocodeine in plasma and in urine and their use to determine the bioavailability of a controlled-release product. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171947/),mg,30,195320,DB00318,Codeine
,31092024,plasma clearance,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),[l] / [h],37.4,196345,DB00318,Codeine
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.035,196346,DB00318,Codeine
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.039,196347,DB00318,Codeine
,11453888,pain,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],91,196963,DB00318,Codeine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],91,196964,DB00318,Codeine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],-,196965,DB00318,Codeine
,11453888,AUC changes,Mean pain AUC changes were 91 score x s(-1) for DHC and -17 score x s(-1) for placebo (95% CI = +/- 36.5 for both treatments).,Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),[score] / [s],17,196966,DB00318,Codeine
,11453888,AIC,"The assumption of a simple linear relationship between DHC concentration and effect provided a significantly better fit than the model containing DHM as the active moiety (AIC = 4.431 vs 4.668, respectively).",Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453888/),,4,196967,DB00318,Codeine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[μg] / [ml],7.95,197087,DB00318,Codeine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],11.0,197088,DB00318,Codeine
,26896302,maximum plasma concentrations,"The geometric mean maximum plasma concentrations of acetaminophen, codeine, and codeine-6-glucuronide were 7.95 μg/mL, 11.0 ng/mL, and 3819 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),[ng] / [ml],3819,197089,DB00318,Codeine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,0.94,197090,DB00318,Codeine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,1.71,197091,DB00318,Codeine
,26896302,terminal half-lives,"The terminal half-lives of acetaminophen, codeine, and codeine-6-glucuronide were 0.94, 1.71, and 3.12 h.",Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896302/),h,3.12,197092,DB00318,Codeine
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,69,198466,DB00318,Codeine
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,21,198467,DB00318,Codeine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,0.9,198696,DB00318,Codeine
,1467165,duration of severe pain,"However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days).",Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),d,2.0,198697,DB00318,Codeine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],40.4,198698,DB00318,Codeine
,1467165,Total body clearance (TBC),Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05).,Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467165/),[ml] / [kg·min],28,198699,DB00318,Codeine
,29389842,apparent half-life,"In contrast to the rapid clearance of dihydrocodeine from blood in the 14-year-old girl (apparent half-life of 3 hours), the 1-month-old baby boy still had high serum concentrations of dihydrocodeine (400 nmol/L) and dihydromorphine (1.9 nmol/L) 21 hours after the last oral administration of dihydrocodeine-containing cough mixture.",Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29389842/),h,3,199906,DB00318,Codeine
,7094509,apparent plasma clearance,"There was a faster, but clinically unimportant, mean apparent plasma clearance in smokers (52.8 +/- 2.3 (SEM) ml/min/70 kg) than in nonsmokers (45.0 +/- 2.1 ml/min/70 kg) after intramuscular injection only.",Codeine disposition in smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),[ml] / [70·kg·min],52.8,200430,DB00318,Codeine
,7094509,apparent plasma clearance,"There was a faster, but clinically unimportant, mean apparent plasma clearance in smokers (52.8 +/- 2.3 (SEM) ml/min/70 kg) than in nonsmokers (45.0 +/- 2.1 ml/min/70 kg) after intramuscular injection only.",Codeine disposition in smokers and nonsmokers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),[ml] / [70·kg·min],45.0,200431,DB00318,Codeine
,7094509,bioavailability,Mean oral codeine bioavailability in smokers (54.8 +/- 4.9%) and in nonsmokers (50.2 +/- 2.1%) did not offer.,Codeine disposition in smokers and nonsmokers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),%,54.8,200432,DB00318,Codeine
,7094509,bioavailability,Mean oral codeine bioavailability in smokers (54.8 +/- 4.9%) and in nonsmokers (50.2 +/- 2.1%) did not offer.,Codeine disposition in smokers and nonsmokers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094509/),%,50.2,200433,DB00318,Codeine
,33581736,MR,The MR of codeine O-demethylation ranged from 0.002 to 0.147 (median 0.018) among all horses.,Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.002 to 0.147,203453,DB00318,Codeine
,33581736,MR,The MR of codeine O-demethylation ranged from 0.002 to 0.147 (median 0.018) among all horses.,Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.018,203454,DB00318,Codeine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.089,203455,DB00318,Codeine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.022,203456,DB00318,Codeine
,33581736,MR,"The mean ± SD MR was 0.089 ± 0.027, 0.022 ± 0.011, and 0.0095 ± 0.001 for high-, moderate-, and low-MR groups, respectively.",Functional phenotyping of the CYP2D6 probe drug codeine in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581736/),,0.0095,203457,DB00318,Codeine
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],64.9,204292,DB00318,Codeine
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],95.2,204293,DB00318,Codeine
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,5807.0,204294,DB00318,Codeine
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,8965.3,204295,DB00318,Codeine
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,45.4,204296,DB00318,Codeine
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,70.1,204297,DB00318,Codeine
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,6,204674,DB00318,Codeine
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,2.9,204675,DB00318,Codeine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,3.6,204950,DB00318,Codeine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.6,204951,DB00318,Codeine
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.7,204952,DB00318,Codeine
,7983238,Cmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],217.8,206467,DB00318,Codeine
,7983238,Cmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],138.8,206468,DB00318,Codeine
,7983238,Tmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.3,206469,DB00318,Codeine
,7983238,Tmax,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,1.1,206470,DB00318,Codeine
,7983238,AUC0-inf,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1202.3,206471,DB00318,Codeine
,7983238,AUC0-inf,"Mean values for single-dose pharmacokinetic parameters for SRC and IRC, respectively, were: Cmax of 217.8 and 138.8 ng/mL; Tmax of 2.3 and 1.1 hours; AUC0-inf of 1202.3 and 1262.4 ng.",Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1262.4,206472,DB00318,Codeine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.6 hours for both formulations.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.6,206473,DB00318,Codeine
,7983238,Cmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],263.8,206474,DB00318,Codeine
,7983238,Cmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),[ng] / [ml],222.9,206475,DB00318,Codeine
,7983238,Tmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,3.2,206476,DB00318,Codeine
,7983238,Tmax,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,1.1,206477,DB00318,Codeine
,7983238,AUC0-12h,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1576.4,206478,DB00318,Codeine
,7983238,AUC0-12h,Their respective mean steady-state pharmacokinetic parameters were: Cmax of 263.8 and 222.9 ng/mL; Tmax of 3.2 and 1.1 hours; AUC0-12h of 1576.4 and 1379.1 ng.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),ng,1379.1,206479,DB00318,Codeine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.8 and 2.3 hours.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.8,206480,DB00318,Codeine
,7983238,t1/2el,mL-1.hour-1; and t1/2el of 2.8 and 2.3 hours.,Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983238/),h,2.3,206481,DB00318,Codeine
,2053119,detection limit,"An original, highly sensitive and specific high-performance liquid chromatographic (HPLC) assay has been developed for the measurement of oxycodone in human plasma with a detection limit of 10 ng/ml using a 1.0-ml plasma sample.",Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053119/),[ng] / [ml],10,208051,DB00318,Codeine
,21417617,half-life,Codeine is an important opioid anti-tussive agent whose short half-life (2.9 ± 0.7 h) requires that it be administered at 4-h intervals when formulated as a simple aqueous solution.,Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,2.9,209665,DB00318,Codeine
,21417617,apparent mean half life,"Controlled release from the suspension of beads protracted the apparent mean half life of codeine from 3.2 h to 8.2 h, while the mean AUC(0-12 h) was unchanged.",Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,3.2,209666,DB00318,Codeine
,21417617,apparent mean half life,"Controlled release from the suspension of beads protracted the apparent mean half life of codeine from 3.2 h to 8.2 h, while the mean AUC(0-12 h) was unchanged.",Pharmacokinetics of a novel liquid controlled release codeine formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21417617/),h,8.2,209667,DB00318,Codeine
,22717418,C(max),"The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16.5% lower.","Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22717418/),%,16.5,210871,DB00318,Codeine
,28421874,maximum plasma concentration,"Oxycodone was detected 8.0 ± 2.7-h postpatch administration, reaching a mean maximum plasma concentration of 3.41 ± 1.34 ng/ml at 49.3 ± 21.2 h.","Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421874/),[ng] / [ml],3.41,212221,DB00318,Codeine
,24077699,clearance,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),[l] / [h],73,214433,DB00318,Codeine
,24077699,oral absorption rate constant,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),h,0.0735,214434,DB00318,Codeine
,22119507,flow rate,"Following liquid-liquid extraction, the analytes were separated on a reversed-phase C(18) column (150 mm × 2.0 mm, 3 μm) using formic acid:10 mM ammonium acetate:methanol (0.2:62:38, v/v/v) as mobile phase at a flow rate of 0.2 mL/min and analyzed by a triple-quadrupole mass spectrometer in the selected reaction monitoring (SRM) mode.","Simultaneous determination of codeine, ephedrine, guaiphenesin and chlorpheniramine in beagle dog plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119507/),[ml] / [min],0.2,215136,DB00318,Codeine
below,6138235,absolute oral bioavailabilities,"The absolute oral bioavailabilities of morphine, codeine, ethylmorphine, and t-butylmorphine all were below 10%, whereas that of pholcodine was over 40%.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),%,10,215170,DB00318,Codeine
over,6138235,absolute oral bioavailabilities,"The absolute oral bioavailabilities of morphine, codeine, ethylmorphine, and t-butylmorphine all were below 10%, whereas that of pholcodine was over 40%.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),%,40,215171,DB00318,Codeine
less,6138235,Terminal half-lives,"Terminal half-lives of morphine, codeine, ethylmorphine, and t-butylmorphine after iv administration all were less than 45 min, while that of pholcoline was over 2 hr.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),min,45,215172,DB00318,Codeine
over,6138235,Terminal half-lives,"Terminal half-lives of morphine, codeine, ethylmorphine, and t-butylmorphine after iv administration all were less than 45 min, while that of pholcoline was over 2 hr.",Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138235/),h,2,215173,DB00318,Codeine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],27.5,216200,DB00318,Codeine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],36.5,216201,DB00318,Codeine
,26814240,Cmax,"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [ml],105.8,216202,DB00318,Codeine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],9.5,216203,DB00318,Codeine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],13.4,216204,DB00318,Codeine
,26814240,Cmax/Tmax),"Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively.","Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814240/),[ng] / [h·ml],82.0,216205,DB00318,Codeine
,17786418,transfer half-life,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),min,21.1,216418,DB00318,Codeine
,17786418,transfer half-life,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),min,19.8,216419,DB00318,Codeine
,17786418,EC50,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),[ng] / [ml],207,216420,DB00318,Codeine
,17786418,EC50,"The transfer half-life between plasma and effect site was 21.1 min (95% CI 11.1-34.7 min) and 19.8 min (95% CI 11.9-34 min) with spline and compartmental approaches, respectively, and miosis occurred with EC50 of 207 or 230 ng/ml, respectively.",Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17786418/),[ng] / [ml],230,216421,DB00318,Codeine
,23835420,transport,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218864,DB00318,Codeine
,23835420,membrane permeability,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218865,DB00318,Codeine
,23835420,KM,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),μM,3.4,218866,DB00318,Codeine
,23835420,VMAX,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[pM] / [mg·min],27,218867,DB00318,Codeine
,23835420,transporter-independent,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218868,DB00318,Codeine
,23835420,membrane permeability,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218869,DB00318,Codeine
,28345745,conversion to OC,Incubation at 80°C for 24 hours in vinegar or vodka produced a conversion to OC of 6 percent.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),%,6,219178,DB00318,Codeine
,28345745,half-life,Incubation with trypsin at 37°C converted PF614 approximately stoichiometric to OC with half-life of 4 hours.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),h,4,219179,DB00318,Codeine
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,0.98,223112,DB00318,Codeine
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,17.01,223113,DB00318,Codeine
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],1.58,223114,DB00318,Codeine
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],414.50,223115,DB00318,Codeine
,10381807,apparent clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],1939,223370,DB00318,Codeine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],162.7,223371,DB00318,Codeine
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],52.7,223372,DB00318,Codeine
,10381807,O,"Codeine O-demethylation was significantly reduced after quinidine in both ethnic groups; however, the absolute decrease was greater in Caucasians (115.8 +/- 25.9 ml/min versus 46.8 +/- 10.6 ml/min, respectively, p <.03).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],115.8,223373,DB00318,Codeine
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,0.97,223560,DB00318,Codeine
,2049245,time to achieve maximum plasma codeine concentrations,"2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,1.28,223561,DB00318,Codeine
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223562,DB00318,Codeine
,2049245,elimination half-life,The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),h,3.2,223563,DB00318,Codeine
,2049245,renal clearance,3. The renal clearance of codeine was 183 +/- 59 ml min-1 and was inversely correlated with urine pH (r = 0.81).,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],183,223564,DB00318,Codeine
,2049245,renal clearance,"The renal clearance of codeine-6-glucuronide was 55 +/- 21 ml min-1, and was not correlated with urine pH.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],55,223565,DB00318,Codeine
less,2049245,binding,Its binding to human plasma was less than 10%.,Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),%,10,223566,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],137,223567,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],8,223568,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],103,223569,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],90,223570,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],914,223571,DB00318,Codeine
,2049245,partial clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],971,223572,DB00318,Codeine
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1568,223573,DB00318,Codeine
,2049245,intrinsic clearance,"6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1.",Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049245/),[ml] / [min],1450,223574,DB00318,Codeine
,27330154,maximum effect (E max ),"Mean maximum effect (E max ) for ""at the moment"" drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001).","Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53,223788,DB00318,Codeine
,27330154,maximum effect (E max ),"Mean maximum effect (E max ) for ""at the moment"" drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001).","Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,66,223789,DB00318,Codeine
,27330154,E max,Drug liking for intact hydrocodone ER was comparable to placebo (E max : 53.9 vs. 53.2).,"Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53.9,223790,DB00318,Codeine
,27330154,E max,Drug liking for intact hydrocodone ER was comparable to placebo (E max : 53.9 vs. 53.2).,"Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27330154/),,53.2,223791,DB00318,Codeine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],9.9,225461,DB00318,Codeine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],20.1,225462,DB00318,Codeine
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],15.4,225463,DB00318,Codeine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.3,225464,DB00318,Codeine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],5.6,225465,DB00318,Codeine
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.2,225466,DB00318,Codeine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,4.4,225467,DB00318,Codeine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,3.6,225468,DB00318,Codeine
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,2.0,225469,DB00318,Codeine
,33515201,half maximal inhibitory concentration (IC50),"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),[ng] / [ml],26.5,226249,DB00318,Codeine
,33515201,Hill factor,"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),,1.05,226250,DB00318,Codeine
,24695355,milk concentration,The mean ibuprofen milk concentration was 360 ± 160 mcg/L.,"Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [l],360,226278,DB00318,Codeine
,24695355,fat milk concentration,"The mean fat milk concentration was 3.23 ± 1.15 g per 100 mL, and the mean milk protein concentration 0.87 ± 0.27 g per 100 mL.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[g] / [100·ml],3.23,226279,DB00318,Codeine
,24695355,milk protein concentration,"The mean fat milk concentration was 3.23 ± 1.15 g per 100 mL, and the mean milk protein concentration 0.87 ± 0.27 g per 100 mL.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[g] / [100·ml],0.87,226280,DB00318,Codeine
,24695355,transfer infant dose,"The ibuprofen transfer infant dose (theoretical infant dose) was 68 mcg·kg-1·d-1 (8-262 mcg·kg-1·d-1), and the relative infant dose was <0.38% (0.04%-1.53%) of the weight-adjusted maternal daily dose, which equals 0.2% of the infant dose.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [d·kg],68,226281,DB00318,Codeine
,24695355,transfer infant dose,"The ibuprofen transfer infant dose (theoretical infant dose) was 68 mcg·kg-1·d-1 (8-262 mcg·kg-1·d-1), and the relative infant dose was <0.38% (0.04%-1.53%) of the weight-adjusted maternal daily dose, which equals 0.2% of the infant dose.","Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 ""Antalait"" study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24695355/),[mcg] / [d·kg],8,226282,DB00318,Codeine
,17690251,pK(i),The pK(i) of JNJ17203212 for recombinant guinea pig TRPV1 was 7.14 +/- 0.06.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.14,227172,DB00318,Codeine
,17690251,pIC(50),JNJ17203212 inhibited both pH (pIC(50) of 7.23 +/- 0.05) and capsaicin (pIC(50) of 6.32 +/- 0.06)-induced channel activation.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.23,227173,DB00318,Codeine
,17690251,pIC(50),JNJ17203212 inhibited both pH (pIC(50) of 7.23 +/- 0.05) and capsaicin (pIC(50) of 6.32 +/- 0.06)-induced channel activation.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,6.32,227174,DB00318,Codeine
,17690251,pIC(50),"In whole-cell patch clamp, the pIC(50) for inhibition of guinea pig TRPV1 was 7.3 +/- 0.01.","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.3,227175,DB00318,Codeine
,17690251,pK(B),"JNJ17203212 demonstrated surmountable antagonism in isolated trachea, with a pK(B) value of 6.2 +/- 0.1.","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,6.2,227176,DB00318,Codeine
,17690251,maximal plasma exposure,"Intraperitoneal administration of 20 mg/kg JNJ17203212 achieved a maximal plasma exposure of 8.0 +/- 0.4 microM, and it attenuated capsaicin evoked coughs with similar efficacy to codeine (25 mg/kg).","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),μM,8.0,227177,DB00318,Codeine
,7818116,terminal half-life,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,3.4,227635,DB00318,Codeine
,7818116,plasma clearance,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [h],45.4,227636,DB00318,Codeine
,7818116,volume of distribution in the terminal phase,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [kg],3.0,227637,DB00318,Codeine
,7818116,absorption lag time,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,0.52,227638,DB00318,Codeine
,7818116,absolute bioavailability,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),%,61.6,227639,DB00318,Codeine
,11361046,pain intensity,Mean (+/- SD) pain intensity (0 = none to 10 = severe) decreased from a baseline of 6.0 +/- 2.2 to 2.7 +/- 1.1 after titration with IR oxycodone dosed qid.,"Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361046/),,6.0,228062,DB00318,Codeine
,25211185,concentration,"Mean tramadol concentration was 14.87 ± 11.14 μg/mL at 0.08 h, and 0.05 ± 0.06 μg/mL at 10 h.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],14.87,228970,DB00318,Codeine
,25211185,concentration,"Mean tramadol concentration was 14.87 ± 11.14 μg/mL at 0.08 h, and 0.05 ± 0.06 μg/mL at 10 h.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.05,228971,DB00318,Codeine
,25211185,maximum concentration (Cmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.05,228972,DB00318,Codeine
,25211185,maximum concentration (Cmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.08,228973,DB00318,Codeine
,25211185,time to achieve maximum concentration (Tmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),h,0.75,228974,DB00318,Codeine
,25211185,time to achieve maximum concentration (Tmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),h,2,228975,DB00318,Codeine
,33404848,AUC,The mean (95% CI) foetal morphine AUC in the CYP2D6 UM cohort of 0.988 (0.902 to 1.073) ng/mL.h was 1.8-fold higher than the CYP2D6 EM cohort of 0.546 (0.492 to 0.600) ng/mL.h (p < 0.001).,Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404848/),[ng] / [h·ml],0.988,230850,DB00318,Codeine
,33404848,AUC,The mean (95% CI) foetal morphine AUC in the CYP2D6 UM cohort of 0.988 (0.902 to 1.073) ng/mL.h was 1.8-fold higher than the CYP2D6 EM cohort of 0.546 (0.492 to 0.600) ng/mL.h (p < 0.001).,Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404848/),[ng] / [h·ml],0.546,230851,DB00318,Codeine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,97,231155,DB00318,Codeine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,92,231156,DB00318,Codeine
,12899973,Extraction efficiencies,"Extraction efficiencies of codeine, morphine and M-3-G from rat plasma samples were 97, 92 and 93%, respectively.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),%,93,231157,DB00318,Codeine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],50,231158,DB00318,Codeine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],25,231159,DB00318,Codeine
,12899973,detection limits,"Using native fluorescence detection (excitation at 245 nm and emission at 345 nm), the detection limits of 50 ng/ml for morphine, 25 ng/ml for codeine and 20 ng/ml for M-3-G were obtained.",The study of codeine-gluthetimide pharmacokinetic interaction in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12899973/),[ng] / [ml],20,231160,DB00318,Codeine
,16729270,volume of the first brain compartment,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,35.4,231787,DB00318,Codeine
,16729270,half-life of equilibrium,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,0.6,231788,DB00318,Codeine
,16729270,half-life,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,7.2,231789,DB00318,Codeine
,16729270,deep cerebral distribution volume,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,222.8,231790,DB00318,Codeine
,16729270,membrane permeability,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],54.8,231791,DB00318,Codeine
,16729270,CBF,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],40,231792,DB00318,Codeine
,16729270,Drug retention in,Drug retention in the brain was 1.3% after 45 min.,Cerebral kinetics of oxycodone in conscious sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),%,1.3,231793,DB00318,Codeine
,7704214,limits of q,"Sensitivity of the method is excellent and allows for the reproducible quantification of dihydrocodeine and dihydromorphine with limits of quantification of 2 ng/ml and 40 pg/ml serum, respectively.",Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704214/),[ng] / [ml],2,231884,DB00318,Codeine
,7704214,limits of q,"Sensitivity of the method is excellent and allows for the reproducible quantification of dihydrocodeine and dihydromorphine with limits of quantification of 2 ng/ml and 40 pg/ml serum, respectively.",Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704214/),[pg] / [ml],40,231885,DB00318,Codeine
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.14,231938,DB00318,Codeine
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.05,231939,DB00318,Codeine
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],19.50,231940,DB00318,Codeine
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],9.72,231941,DB00318,Codeine
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,22.10,231942,DB00318,Codeine
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,20.50,231943,DB00318,Codeine
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,353,231944,DB00318,Codeine
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,291,231945,DB00318,Codeine
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],25,234545,DB00318,Codeine
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],50,234546,DB00318,Codeine
,16044107,initial delivery rate,"For 6 patients, the initial delivery rate was 75-150 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],75-150,234547,DB00318,Codeine
,16044107,bioavailability,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),%,78,234548,DB00318,Codeine
,16044107,total clearance,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],41,234549,DB00318,Codeine
>,16044107,total clearance,"At the 2 highest doses, an increase of total clearance was observed (>60 L/h).",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],60,234550,DB00318,Codeine
,23719682,apparent oral central volume of distribution,"The population estimates of apparent oral central volume of distribution and apparent oral linear clearance were 714 L and 64.4 L/h, respectively.",Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719682/),l,714,235282,DB00318,Codeine
,23719682,apparent oral linear clearance,"The population estimates of apparent oral central volume of distribution and apparent oral linear clearance were 714 L and 64.4 L/h, respectively.",Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719682/),[l] / [h],64.4,235283,DB00318,Codeine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],0.57,239351,DB00318,Codeine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],0.80,239352,DB00318,Codeine
,8926732,Peak hair codeine concentrations,"Peak hair codeine concentrations for the 5-, 10-, and 20-mg/kg groups occurred 20 days after beginning the dosing protocol and were 0.57 +/- 0.13, 0.80 +/- 0.10, and 1.95 +/- 0.35 ng/mg hair, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.95,239353,DB00318,Codeine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.08,239354,DB00318,Codeine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],1.21,239355,DB00318,Codeine
,8926732,peak concentrations,"Morphine peak concentrations occurred at the same time and were 1.08 +/- 0.28, 1.21 +/- 0.09, and 2.10 +/- 0.26 ng/mg hair for the 5-, 10-, and 20-mg/kg groups, respectively.",Distribution of codeine and morphine into rat hair after long-term daily dosing with codeine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926732/),[ng] / [hair·mg],2.10,239356,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,240,241360,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,163,241361,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),,123,241362,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],309,241363,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],251,241364,DB00318,Codeine
,1540490,concentrations,"The mean concentrations of codeine at 3, 4 and 5 h after administration were 240, 163 and 123 nmol l-1 in the younger and 309, 251 and 169 nmol l-1 in the older patients.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),[nM] / [l],169,241365,DB00318,Codeine
,1540490,plasma half-lives,4. In the infants the mean plasma half-lives of codeine and morphine were 2.6 and 2.5 h.,Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),h,2.6,241366,DB00318,Codeine
,1540490,plasma half-lives,4. In the infants the mean plasma half-lives of codeine and morphine were 2.6 and 2.5 h.,Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),h,2.5,241367,DB00318,Codeine
,1540490,concentration ratio,"5. The mean morphine/codeine concentration ratio was 4.3% in the infants and 1.6% in the children, suggesting impaired glucuronidation of morphine in the former group.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),%,4.3,241368,DB00318,Codeine
,1540490,concentration ratio,"5. The mean morphine/codeine concentration ratio was 4.3% in the infants and 1.6% in the children, suggesting impaired glucuronidation of morphine in the former group.",Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540490/),%,1.6,241369,DB00318,Codeine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],13.9,242602,DB00318,Codeine
,9129563,peak serum concentration,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[pM] / [ml],0.68,242603,DB00318,Codeine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],27.8,242604,DB00318,Codeine
,9129563,area under the serum concentration-time curve,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),[h·pM] / [ml],1.9,242605,DB00318,Codeine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.160,242606,DB00318,Codeine
,9129563,total amount of morphine excreted in urine,"The pharmacokinetic parameters (mean +/- SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9 +/- 10.5 versus 0.68 +/- 0.15 pmol/ml; area under the serum concentration-time curve, 27.8 +/- 16.0 versus 1.9 +/- 0.7 hr.pmol/ml; total amount of morphine excreted in urine, 0.160 +/- 0.036 versus 0.015 +/- 0.007 mumol).",Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129563/),μM,0.015,242607,DB00318,Codeine
,16763013,CL(in),CL(in) across the BBB was estimated to 1910 microl/min x g brain.,In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),[μl] / [g·min],1910,244789,DB00318,Codeine
,16763013,"K(p,uu)","K(p,uu) was estimated to 3.0, meaning that the unbound concentration of oxycodone in brain was 3 times higher than in blood, which is an indication of active influx of oxycodone at the BBB.",In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),,3.0,244790,DB00318,Codeine
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],1.0 to 256.0,244815,DB00318,Codeine
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],0.9-269.4,244816,DB00318,Codeine
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,68,246405,DB00318,Codeine
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,60,246406,DB00318,Codeine
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,59,246407,DB00318,Codeine
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,63,246408,DB00318,Codeine
,3335120,elimination half-life,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,18.69,247486,DB00318,Codeine
,3335120,elimination half-life,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,4.04,247487,DB00318,Codeine
,3335120,mean residence time,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,12.77,247488,DB00318,Codeine
,3335120,mean residence time,"Codeine elimination half-life and mean residence time were increased significantly in the hemodialysis group (18.69 +/- 9.03 hours and 12.77 +/- 7.09 hours, mean +/- SD, respectively) compared with the healthy volunteer group (4.04 +/- 0.60 hours and 3.90 +/- 0.52 hours, respectively).",Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335120/),h,3.90,247489,DB00318,Codeine
,1958450,t1/2z,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),min,222,251145,DB00318,Codeine
,1958450,CL,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [min],0.78,251146,DB00318,Codeine
,1958450,Vss,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [kg],2.60,251147,DB00318,Codeine
,1958450,"AUC(0,12) ratio","The mean AUC(0,12) ratio of noroxycodone to oxycodone was 0.33.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),,0.33,251148,DB00318,Codeine
,32654915,Cmax,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],270.7,252585,DB00318,Codeine
,32654915,tmax,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),h,0.438,252586,DB00318,Codeine
,32654915,elimination t½,"The Cmax, tmax and elimination t½ were 270.7 ± 136.0 ng mL-1, 0.438 ± 0.156 hours and 2.00 ± 0.534 hours, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),h,2.00,252587,DB00318,Codeine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],492.7,252588,DB00318,Codeine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],96.1,252589,DB00318,Codeine
,32654915,Cmax,"M3G was the main metabolite detected (Cmax 492.7 ± 35.5 ng mL-1), followed by C6G (Cmax 96.1 ± 33.8 ng mL-1) and M6G (Cmax 22.3 ± 4.96 ng mL-1).","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],22.3,252590,DB00318,Codeine
,32654915,Cmax,"Morphine and norcodeine were the least abundant metabolites with Cmax of 3.17 ± 0.95 and 1.42 ± 0.79 ng mL-1, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],3.17,252591,DB00318,Codeine
,32654915,Cmax,"Morphine and norcodeine were the least abundant metabolites with Cmax of 3.17 ± 0.95 and 1.42 ± 0.79 ng mL-1, respectively.","Metabolism, pharmacokinetics and selected pharmacodynamic effects of codeine following a single oral administration to horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32654915/),[ng] / [ml],1.42,252592,DB00318,Codeine
,8926744,hair concentration,"in female subjects, the mean (plus or minus standard error of the mean) hair concentration of codeine in the proximal, 1-cm segment from plucked hair was 2.7 ng/mg (+/- 0.55) at 12 h after the last codeine dose; 0.44 ng/mg (+/- 0.20) still remained in this segment at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],2.7,253905,DB00318,Codeine
,8926744,hair concentration,"in female subjects, the mean (plus or minus standard error of the mean) hair concentration of codeine in the proximal, 1-cm segment from plucked hair was 2.7 ng/mg (+/- 0.55) at 12 h after the last codeine dose; 0.44 ng/mg (+/- 0.20) still remained in this segment at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],0.44,253906,DB00318,Codeine
,8926744,hair concentration,"In male subjects studied previously, the mean hair concentration of codeine in the proximal, 1-cm hair segment was 2.6 ng/mg (+/- 0.34) at 12 h after the last codeine dose, and no codeine was detected at 5 weeks.",Disposition of codeine in female human hair after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926744/),[ng] / [mg],2.6,253907,DB00318,Codeine
,31691978,effective permeability,"Based on experiments in Caco-2 cell monolayers, the effective permeability of dihydrocodeine in human jejunum was established as 1.28 × 10-4 cm/s.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[cm] / [s],1.28 × 10-4,255905,DB00318,Codeine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [min·pM],0.19,255906,DB00318,Codeine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [min·pM],0.066,255907,DB00318,Codeine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [mg·min],0.14,255908,DB00318,Codeine
,31691978,Vmax /Km,"The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 μl/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 μl/min/mg protein, respectively.",Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[μl] / [mg·min],0.22,255909,DB00318,Codeine
,31691978,Renal clearance,Renal clearance was calculated as 5.37 L/h on the total clearance value multiplied by the fraction recovered in urine.,Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31691978/),[l] / [h],5.37,255910,DB00318,Codeine
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],48.6,256793,DB00318,Codeine
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],36.3,256794,DB00318,Codeine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,4349,256896,DB00318,Codeine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,2564,256897,DB00318,Codeine
,8823235,total recovered amount,"The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823235/),nM,1127,256898,DB00318,Codeine
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,1-2,259209,DB00318,Codeine
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,0.5-1,259210,DB00318,Codeine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,1.02,259836,DB00318,Codeine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,2.46,259837,DB00318,Codeine
,6470567,t1/2,"The t1/2 of morphine was significantly prolonged from 1.02 +/- 0.50 hours (mean +/- SD) to 2.46 +/- 2.68 hours (p = 0.03) after transfusion with stroma-free hemoglobin, and to 2.05 +/- 0.95 hours (p = 0.006) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),h,2.05,259838,DB00318,Codeine
,6470567,volume of distribution,The volume of distribution was increased from 1.35 +/- 0.81 L X kg-1 to 2.99 +/- 1.45 L X kg-1 (p = 0.004) after transfusion with stroma-free hemoglobin; no such difference was observed after transfusion with fluosol DA (p = 0.86).,Interaction of oxygen-carrying resuscitation fluids with morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [kg],1.35,259839,DB00318,Codeine
,6470567,volume of distribution,The volume of distribution was increased from 1.35 +/- 0.81 L X kg-1 to 2.99 +/- 1.45 L X kg-1 (p = 0.004) after transfusion with stroma-free hemoglobin; no such difference was observed after transfusion with fluosol DA (p = 0.86).,Interaction of oxygen-carrying resuscitation fluids with morphine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [kg],2.99,259840,DB00318,Codeine
,6470567,area under the time-concentration curve,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[h·mg] / [l],2.37,259841,DB00318,Codeine
,6470567,area under the time-concentration curve,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[h·mg] / [l],6.02,259842,DB00318,Codeine
,6470567,total body clearance,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [h·kg],1.02,259843,DB00318,Codeine
,6470567,total body clearance,"The area under the time-concentration curve was increased from 2.37 +/- 1.78 mg X hr X L-1 to 6.02 +/- 6.61 mg X hr X L-1 (p = 0.02), and total body clearance was decreased from 1.02 +/- 0.53 L X hr-1 X kg-1 to 0.55 +/- 0.36 L X hr-1 X kg-1 (p = 0.01) after transfusion with Fluosol DA.",Interaction of oxygen-carrying resuscitation fluids with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470567/),[l] / [h·kg],0.55,259844,DB00318,Codeine
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,11.5,259884,DB00318,Codeine
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,14,259885,DB00318,Codeine
,34228875,oral bioavailability,"Furthermore, oral bioavailability was 14.4% higher in patients compared to healthy volunteers regardless of formulation type (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),%,14.4,259886,DB00318,Codeine
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],60,260908,DB00318,Codeine
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],52,260909,DB00318,Codeine
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],98,260910,DB00318,Codeine
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],80,260911,DB00318,Codeine
,12501913,plasma elimination half-life,"In opiate-naïve subjects, intravenous (i.v.) ACOD showed a plasma elimination half-life of 237 +/- 18 min, urine peak concentrations 2 h after administration, and a detection window of 8 h.",Acetylcodeine as a urinary marker to differentiate the use of street heroin and pharmaceutical heroin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501913/),min,237,260935,DB00318,Codeine
<,7586928,metabolic ratio [MR],"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,1,261923,DB00318,Codeine
<,7586928,1,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261924,DB00318,Codeine
>,7586928,MR,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261925,DB00318,Codeine
,7586928,area under the serum concentration-time curve (AUC),"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[h·nM] / [l],10.3,261926,DB00318,Codeine
,7586928,partial metabolic clearance,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[ml] / [min],7.0,261927,DB00318,Codeine
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,1.3,261928,DB00318,Codeine
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,8.9,261929,DB00318,Codeine
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],125.4,262297,DB00318,Codeine
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],57.2,262298,DB00318,Codeine
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],2561,262299,DB00318,Codeine
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],1095,262300,DB00318,Codeine
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,5.0,262301,DB00318,Codeine
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,8.0,262302,DB00318,Codeine
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.8,262303,DB00318,Codeine
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.4,262304,DB00318,Codeine
,26352950,maximum plasma concentration,The results indicate that the plasma levels of parent tramadol are low or negligible during the first 30-45 min and then reach the predicted mean maximum plasma concentration of 358 ng/ml at 1.52 hr.,"PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE AND ITS METABOLITE O-DESMETHYLTRAMADOL FOLLOWING A SINGLE, ORALLY ADMINISTERED DOSE IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352950/),[ng] / [ml],358,262760,DB00318,Codeine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.45,266219,DB00318,Codeine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.65,266220,DB00318,Codeine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,4.80,266221,DB00318,Codeine
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.40,266222,DB00318,Codeine
,1485370,plasma clearance,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [h],25.5,266223,DB00318,Codeine
,1485370,volume of distribution at steady state,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [kg],2.5,266224,DB00318,Codeine
,1485370,normalized area under the curve (AUC/D),"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],48.2,266225,DB00318,Codeine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],19.8,266226,DB00318,Codeine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],17.5,266227,DB00318,Codeine
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],20.3,266228,DB00318,Codeine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.52,266229,DB00318,Codeine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.48,266230,DB00318,Codeine
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.76,266231,DB00318,Codeine
,26108255,Tmax,Median Tmax for crushed OxyContin® was the same as IR oxycodone and 3.25 hours shorter than intact OxyContin®.,Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26108255/),h,3.25,269263,DB00318,Codeine
,30189012,clearance,The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),[l] / [h],8.4,271360,DB00318,Codeine
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,3.9,271361,DB00318,Codeine
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,5.7,271362,DB00318,Codeine
,7975724,maximum concentrations,"Plasma concentrations of unchanged dihydrocodeine were significantly lower after oral rather than intramuscular administration; the maximum concentrations were 40 and 549 ng/ml after oral and intramuscular administration, respectively.",Metabolism and pharmacokinetics of dihydrocodeine in dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975724/),[ng] / [ml],40,273016,DB00318,Codeine
,7975724,maximum concentrations,"Plasma concentrations of unchanged dihydrocodeine were significantly lower after oral rather than intramuscular administration; the maximum concentrations were 40 and 549 ng/ml after oral and intramuscular administration, respectively.",Metabolism and pharmacokinetics of dihydrocodeine in dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7975724/),[ng] / [ml],549,273017,DB00318,Codeine
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],22.4,273696,DB00318,Codeine
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],26.8,273697,DB00318,Codeine
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,33,273698,DB00318,Codeine
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,19.5,273699,DB00318,Codeine
,9706948,Tmax,The Tmax value for codeine (63.3 +/- 11.7) was greater than that for tramadol (P = 0.034).,"A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),,63.3,273700,DB00318,Codeine
